Phase II Study to Evaluate Safety & Immunogenicity of a Chikungunya

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of a novel vaccine against Chikungunya virus after one or two vaccinations by comparison of two different dose levels.

Clinical Trial Description

This is a double blinded, block-randomized, active- and placebo controlled, phase II trial, comparing two dose levels by assessing immunogenicity, safety and tolerability of MV-CHIK (a novel vaccine against Chikungunya virus). Healthy male and female subjects aged 18-55 years will be randomized to one of six treatment groups (A, B, C. D, M1 or M2) differing in dosage and scheduling of vaccinations. Group A-D will be split in one arm receiving MV-CHIK and one control-arm receiving Priorix®. All subjects of group A. B, C and D will receive three i.m. injections on study day 0, 28 and 196. Subjects of group A and B will receive MV-CHIK low dose or control-vaccine Priorix® (or equivalent measles vaccine) and subjects of group C and D will be treated with MV-CHIK high dose or control-vaccine (Priorix® or equivalent measles vaccine). All subjects of group A, B, C and D additionally will be randomized to one of two treatment sequences: group A and C will receive MV-CHIK or control-vaccine Priorix® on study day 0 and 28, followed by placebo on day 196, and group B and D receive placebo on day 0 and MV-CHIK or Priorix® on day 28, followed by an additional vaccination of the same product on day196 (boosting vaccination). All subjects of the measles booster group M1 and M2 will receive five i.m. injections on study day -28, 0, 28, 168 and 196. The first vaccination will be Priorix® (or equivalent measles vaccine) on study day -28. Group M1 will receive MV-CHIK vaccinations on day 0 and day 28 and placebo on day 168 and 196. Group M2 will receive placebo on day 0 and 28 and MV-CHIK on day 168 and on day 196. All subjects will be followed for safety and immunogenicity evaluation until day 224. Study duration per subject is estimated to be 33-37 weeks (~8 months), respectively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02861586
Study type	Interventional
Source	Themis Bioscience GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	August 17, 2016
Completion date	April 16, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02230163` - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins	Phase 1/Phase 2
Completed	`NCT04546724` - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults	Phase 3
Terminated	`NCT04455919` - Yoga for Chronic Chikungunya	N/A
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting	`NCT04441905` - Phase 1 Study of SAR440894 vs Placebo	Phase 1
Completed	`NCT02562482` - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults	Phase 2
Completed	`NCT03028441` - Phase I Trial of Measles Vectored Chikungungya Vaccine	Phase 1
Completed	`NCT03807843` - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)	Phase 2
Completed	`NCT04909411` - Consequences of a Maternal-fetal Chikungunya Virus Infection	N/A
Completed	`NCT04786444` - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults	Phase 3
Completed	`NCT02553369` - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection	N/A
Recruiting	`NCT06106581` - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years	Phase 2
Recruiting	`NCT06007183` - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination	Phase 3
Completed	`NCT03635086` - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)	Phase 2
Active, not recruiting	`NCT04838444` - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)	Phase 3
Completed	`NCT03483961` - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults	Phase 2
Recruiting	`NCT06028841` - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine — MV-CHIK-202

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms